894789-28-7

Basic information

• Product Name: (S)-N-Cbz-pyranyl glycine methyl ester
• Synonyms: (S)-N-Cbz-pyranyl glycine methyl ester
• CAS NO: 894789-28-7
• Molecular Weight: 307.346
• Mol File: 894789-28-7.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: (S)-N-Cbz-pyranyl glycine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Cbz-pyranyl glycine methyl ester(894789-28-7)
• EPA Substance Registry System: (S)-N-Cbz-pyranyl glycine methyl ester(894789-28-7)

Safety Data

• Hazardous Substances Data: 894789-28-7(Hazardous Substances Data)

Upstream product

• 477585-43-6 methyl 2-amino-2-(tetrahydro-2H-pyran-4-yl)acetate 
• 501-53-1 benzyl chloroformate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 
• 477584-90-0 methyl 2-(((benzyloxy)carbonyl)amino)-2-(dihydro-2H-pyran-4(3H)-ylidene)acetate 
• 950192-18-4 racemic Cbz-pyranylglycine methyl ester 

Downstream Products

• 1009120-03-9 (S)-methoxycarbonylamino(tetrahydropyran-4-yl)acetic acid 
• 1035279-38-9 C₃₃H₄₃N₅O₅ 
• 1035278-84-2 C₂₈H₃₅N₅O₃ 
• 368866-32-4 (S)-pyranylglycine methyl ester 

Relevant articles and documents

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.